

OCT 31 2003  
PATENT & TRADEMARK OFFICE

PTO/SB/08 (08-03)

Substitute for form PTO/SB/08 <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> (use as many sheets as necessary)				<b>Complete If Known</b>	
				<i>Application Number</i>	10/631,258
				<i>Filing Date</i>	July 31, 2003
				<i>First Named Inventor</i>	Meares, Claude
				<i>Art Unit</i>	Not yet assigned
				<i>Examiner Name</i>	Not yet assigned
				<i>Attorney Docket Number</i>	023070-130920US
Sheet	1	of	1		

U.S. PATENT DOCUMENTS+					
Examiner Initials*	Cite No. <sup>1</sup>	Document Number Number Kind Code <sup>2</sup> (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
SK	AA	US 2003/124057	07/03/2003	Griffiths et al.	

FOREIGN PATENT DOCUMENTS								
Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document			Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>2</sup>
		Country Code	Number <sup>2</sup>	Kind Code <sup>3</sup> (if known)				
	AB	WO	00/74729	A2	12/14/2000	Center for Molecular Medicine and Immunology		<input type="checkbox"/>

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials *	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
SK	AC	GOODWIN, David A. et al.; "Pharmacokinetics of pretargeted monoclonal antibody 2D12.5 and <sup>90</sup> Y-Janus-2-(p-nitrobenzyl)-1,4,7,10-tetraazacyclododecanetetraacetic acid (DOTA) in BALB/c mice with KHJJ mouse adenocarcinoma: A model for <sup>90</sup> Y radioimmunotherapy"; <u>Cancer Research</u> ; November 15, 1994; pp. 5937-5946; Vol. 54.	
	AD	KARACAY, H. et al.; "Pretargeting for cancer radioimmunotherapy with bispecific antibodies: Role of the bispecific antibody's valency for the tumor target antigen"; <u>Bioconjugate Chem.</u> ; 2002; pp. 1054-1070; Vol. 13; USA	
	AE	LUBIC, Stephen P. et al.; "Biodistribution and dosimetry of pretargeted monoclonal antibody 2D12.5 and Y-Janus-DOTA in BALB/c mice with KHJJ mouse adenocarcinoma"; <u>The Journal of Nuclear Medicine</u> ; April 2001; pp. 670-678; Vol. 42., No. 4	
	AF	STICKNEY, Dwight R. et al.; "Bifunctional antibody: A binary radiopharmaceutical delivery system for imaging colorectal carcinoma"; <u>Cancer Research</u> ; December 15, 1991; pp. 6650-6655; Vol. 51.	
SK	AG	WALDHERR, Christian et al.; "Tumor response and clinical benefit in neuroendocrine tumors after 7.4 GBq <sup>90</sup> Y-DOTATOC"; <u>The Journal of Nuclear Medicine</u> ; May 2002; pp. 610-616; Vol. 43, No. 5	

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

\* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.